Clinical effect of Kangfu Xiaoyan suppository combined with moxifloxacin in the treatment of chronic pelvic inflammatory disease / 中国基层医药

ABSTRACT

Objective@#To explore the clinical effect of Kangfu Xiaoyan suppository combined with moxifloxacin in the treatment of chronic pelvic inflammatory disease.@*Methods@#From November 2016 to November 2018, a total of 216 patients with chronic pelvic inflammatory disease admitted to the Maternal and Child Health Care Hospital of Lishui were enrolled.The patients were divided into control group and observation group according to the digital table, with 108 cases in each group.The patients in the control group were treated with quinolone antibacterial agent moxifloxacin hydrochloride tablets.The patients in the observation group were treated with Kangfu Xiaoyan suppository and moxifloxacin hydrochloride tablets.The disappearance time of clinical signs, clinical treatment effects and adverse reactions in the two groups after treatment were observed and compared.@*Results@#The disappearance time of fever[(5.15±2.46)h], lower abdominal pain[(7.62±2.77)h], leucorrhea abnormality[(9.16±3.13)h], and pain[(6.38±2.03)h] in the observation group were significantly shorter than those in the control group[(8.09±2.28)h, (10.45±2.68)h, (12.20±2.96)h, (9.49±2.27)h](t=8.231, 7.631, 7.334, 10.613, all P=0.000). The total effective rate of the observation group (93.51%) was significantly higher than that of the control group (86.11%), the difference was statistically significant (χ2=6.983, P=0.008). The overall incidence of adverse reactions of the observation group (3.70%) was significantly lower than that of the control group (11.11%), and the difference was statistically significant (χ2=4.32, P=0.038).@*Conclusion@#Compared with the simple use of moxifloxacin, Kangfu Xiaoyan suppository combined with moxifloxacin in the treatment of gynecological chronic pelvic inflammatory disease has a better clinical treatment effect and a lower incidence of adverse reactions.It is recommended to apply in clinical treatment in the future.